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Randomized controlled trials are often used to inform policy and practice for broad popula-
tions. The average treatment effect (ATE) for a target population, however, may be different 
from the ATE observed in a trial if there are effect modifiers whose distribution in the target 
population is different that from that in the trial. Methods exist to use trial data to estimate the 
target population ATE, provided the distributions of treatment effect modifiers are observed 
in both the trial and target population—an assumption that may not hold in practice.
Methods
The proposed sensitivity analyses address the situation where a treatment effect modifier is 
observed in the trial but not the target population. These methods are based on an outcome 
model or the combination of such a model and weighting adjustment for observed differ-
ences between the trial sample and target population. They accommodate several types of 
outcome models: linear models (including single time outcome and pre- and post-treatment 
outcomes) for additive effects, and models with log or logit link for multiplicative effects. We 
clarify the methods’ assumptions and provide detailed implementation instructions.
Illustration
We illustrate the methods using an example generalizing the effects of an HIV treatment 
regimen from a randomized trial to a relevant target population.
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Conclusion
These methods allow researchers and decision-makers to have more appropriate confi-
dence when drawing conclusions about target population effects.
Introduction
Randomized controlled trials (trials) are often used to inform policy and practice for broad
populations. A well designed and implemented trial allows consistent estimation of the average
treatment/intervention effect (ATE) for the trial sample. We refer to this as the Study-specific
ATE (SATE). If the question is whether that treatment should be used for people in a certain
population (target population), then of interest is the Target population ATE (TATE). Since
trial samples are often not representative of target populations, SATE may not be a good esti-
mate of TATE. SATE departs from TATE if the trial sample differs from the target population
with respect to the distribution of treatment effect modifiers.
Methods exist to use trial data to estimate TATE, e.g., [1–3], assuming treatment effect vari-
ation is explained by pre-treatment variables that are observed in both the trial and target pop-
ulation. Often, however, the variables observed for the target population are limited compared
to those measured in the trial [4, 5]. This paper presents simple methods to assess the sensitiv-
ity of TATE estimates to effect modifiers observed in the trial but not in the target population.
The paper starts from the simple case of additive effects based on an uncomplicated linear
model (previously addressed in [6]) and extends to cases with more complex models and mul-
tiplicative effects. We clarify the assumptions of these methods for a general audience and pro-
vide detailed implementation instructions.
We illustrate the sensitivity analyses using an example based on the AIDS Clinical Trial
Group (ACTG) 320 Study [7]. This trial randomized HIV-infected adults to two antiretroviral
regimens: (i) two nucleoside reverse-transcriptase inhibitors (AZT or d4T and 3TC) plus a
protease inhibitor (Indinavir), and (ii) AZT/d4T and 3TC only—referred to as new and old
treatment, respectively. The trial found that relative to the old treatment, the new treatment
lowered the hazard of AIDS and/or death. Cole & Stuart [1] generalized this effect to the popu-
lation of people diagnosed with HIV in the US in 2006, using a set of covariates observed in
both the trial and target population. Our example is based on this trial-population pair. We
consider a different outcome, CD4 count (number of T-CD4 cells per ml blood), which is an
important indicator of immunity status. We use the same target population dataset that Cole
& Stuart created for [1] based on the CDC-estimated joint distribution of demographic charac-
teristics in this population [8]. As the trial data are not for open access, for this illustration, we
use a synthetic trial dataset created to mimic the distributions in the real trial data.
Methods for the simplest case: Additive effects on potential
outcome based on a linear causal model
For this case, the basic mathematical results of the methods and one of their key assumptions
were developed in [6]. The current paper elaborates on the full set of assumptions required by
these methods, and pays close attention to details relevant to their effective use, such as differ-
ent data scenarios and corresponding implementation instructions, including variation in
weighting procedures for the method that involves weighting.
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Trial sample, target population data, effect definitions
Consider a trial evaluating the effect of treatment A on outcome Y. Let S = 1 denote trial partic-
ipation, P = 1 denote membership in the target population. In Fig 1, the trial sample is drawn
from the target population (i.e., individuals i with Si = 1 also have Pi = 1); and the purpose is to
generalize trial results back to the target population. If the trial sample is drawn from a differ-
ent population (i.e., S = 1 is outside of P = 1), the problem is to transport [9] results to the tar-
get population.
We present the methods using a binary treatment. Let Yi(a) denote individual i’s potential
outcome [10] if treatment were set to a, with a = 1, 0 (treatment or control). Treatment effect
for individual i is defined on the additive scale as Yi(1) − Yi(0), the difference between potential
outcomes under treatment and under control.
SATE is defined as the average treatment effect in the trial sample, E[Y(1) − Y(0)|S = 1].
Due to randomization, SATE is unbiasedly estimated, for example, by the difference in
mean outcome between the trial’s treatment arms. Of interest, however, is TATE, defined as
E[Y(1) − Y(0)|P = 1], the average treatment effect in the target population.
The sensitivity analyses require data on the distribution of pre-treatment covariates in the
target population. Such data may come from a full population (P = 1) dataset, a representative
(S = 2) sub-sample, or population summary statistics (see Fig 1).
Assumptions
Several assumptions are required. The first assumption is that the trial has internal validity
(A1), which itself consists of several conditions listed in Table 1. We will not discuss interval
validity further, but this is a key assumption. On top of this, we need a set of assumptions com-
monly used in generalization [1–3]: across-setting treatment variance irrelevance (A2), trial
coverage of target population ranges of the effect modifiers (A3), conditional ignorability for
treatment effects (A4), and consistent measurement and no measurement error (A5)—see
detailed explanations of and practical comments on these assumptions in Table 1.
Assumptions A1-A5 are sufficient for estimating TATE if all effect modifiers are observed
in both the trial and target population, via either G-computation or weighting the trial sample
to the target population [1–3, 11, 12]. When some effect modifiers are not observed in the tar-
get population, however, such strategies fail. In this case, in order to use the proposed sensitiv-
ity analyses to glean some information on TATE, we make the additional assumption (A6) of a
Fig 1. Several data source scenarios for generalization from the trial (S = 1) to the target population (P = 1). (a) the trial sample
and a full population dataset; (b) the trial sample and a dataset (S = 2) that is representative of the population; (c) the trial sample and
some summary statistics about the population.
https://doi.org/10.1371/journal.pone.0208795.g001
causal model. In this section we assume the linear causal model
E½YiðaÞ� ¼ b0 þ baaþ bxXi þ bzZi þ bzaZiaþ bvVi þ bvaVia; ðM1Þ
where potential outcomes are influenced by treatment condition a and baseline covariates
X, Z, V, all observed in the trial. X, Z and V may be multivariate; the use of univariate notation
is to simplify presentation. Z and V both denote effect modifiers; the difference is Z is observed
in the target population while V is not.
(The letter M in the equation label M1 indicates that this is a causal model. We will also use
T in labels to indicate TATE formulas, and R to indicate regression models).
This model assumption should not be made lightly. With a binary outcome, for instance,
this model would imply additive effects on the risk difference scale, which may be inappropriate.
Table 1. Key assumptions.
Assumption Details
A1. Internal validity of the trial We make all the assumptions required for the trial’s internal validity,
e.g., conditional ignorability of treatment assignment, positivity,
treatment variance irrelevance, no interference, etc.
A2. Across-setting treatment variation
irrelevance
When a treatment is applied to the target population, it is administered
in settings that are likely different from the trial setting. The
assumption is that the differences in the treatment that result do not
change its effect.
This assumption is non-trivial in some settings and should be
examined explicitly in generalization practice. In this paper, we simply
make the assumption; its plausibility is not the problem we currently
aim to discuss.
A3. Treatment effect modifiers coverage Treatment effects depend on a set of pre-treatment variables observed
in the trial (denoted Z if observed and V if not observed in the target
population), and the range of these (observed and unobserved) effect
modifiers in the target population is covered by their range in the trial.
The rationale is that if there are members of the target population with
effect modifier values outside the range observed in the trial, we cannot
use trial data to learn about their treatment effects. This assumption,
which is similar to positivity, is formally Pr(S = 1|Z = z, V = v) > 0 if Pr
(Z = z, V = v|P = 1) > 0 where Pr[�] is the probability function [17].
This assumption can be checked for Z variables but not for V.
A4. Conditional sample ignorability for
treatment effects [3]
For an individual (in the trial or the target population) with effect
modifiers within the target population range, “sample membership”
(i.e., whether the individual is in the trial or in the target population)
does not carry any information about the treatment effect once we
condition on the effect modifiers. For additive effects, this is formally
[Y(1) − Y(0)]⫫ {S, P}jZ, V, (S = 1 or P = 1).
This assumption allows generalizing treatment effects from individuals
in the trial to individuals in the target population with similar patterns
of the effect modifiers.
This assumption is less strict than conditional sample ignorability for
potential outcomes, {Y(1), Y(0)}⫫ {S, P}jX, Z, V, (S = 1 or P = 1) where
X denotes predictors of the potential outcomes that are not part of the
set of effect modifiers {Z, V}. Yet this assumption is tied to the scale on
which effects are defined.
A5. Consistent measurement and no
measurement error
The trial’s internal validity requires no systematic measurement error
of a continuous outcome and no misclassification of a categorical
outcome. Here we also need to assume that all covariate measurements
are without error, and that X and Z are measured the same way
between the trial and the target population.
A6. A specific causal model We assume a causal model with effect modification; effects should be
defined on a scale that connects naturally to the model.
The main methods section assumes a linear causal model (with
interaction terms) and defines effects on the additive scale.
https://doi.org/10.1371/journal.pone.0208795.t001
(See the next section for an extension of these methods to a broader class of models). Also, the
selection of which pre-treatment variables to include in the model and which variables to con-
sider effect modifiers requires serious investigation, and is discussed is great length in relevant
literature, e.g., [13–16]. With the current focus on sensitivity analysis, we presume that such a
model has been selected. If unsure whether a variable is an effect modifier (e.g., because its inter-
action with treatment has a non-negligible coefficient but its p-value is large), our recommenda-
tion is to treat it as one for the purpose of TATE estimation, since trials usually lack power to
investigate effect modification.
TATE formula
Based on the causal model M1, individual i’s treatment effect has expectation E[Yi(1) − Yi(0)]
= βa + βza Zi + βva Vi, therefore
TATE ¼ ba þ bzaE½ZjP ¼ 1� þ bvaE½VjP ¼ 1�; ðT1Þ
where E[Z|P = 1] and E[V|P = 1] are the means of Z and V in the target population. Under
Assumptions A1-A6, βa, βza and βva are the same for the trial sample and target population,
and can be estimated using trial data.
The problematic quantity in this formula is E[V|P = 1], because we do not observe V in
the target population. However, if we specify a plausible range for E[V|P = 1] (the sensitivity
parameter), we obtain a range of TATE estimates. We outline here two ways to do this, and
provide detailed implementation instructions in Table 2.
Method 1: Outcome-model-based sensitivity analysis
This method requires an estimate for E[Z|P = 1] (target population mean Z), but not a target
population dataset. It involves: (1) obtaining an estimate for E[Z|P = 1]; (2) specifying a plausi-
ble range for the sensitivity parameter E[V|P = 1]; (3) fitting to trial data the regression model
E½YjA;X;Z;V� ¼ b0 þ baAþ bxX þ bzaZAþ bvV þ bvaVA; ðR1Þ
(4) combining the estimated E[Z|P = 1] and specified E[V|P = 1] with model coefficients to
obtain TATE estimates (using formula T1); and (5) plotting results against the sensitivity
parameter.
Method 2: Weighted-outcome-model-based sensitivity analysis
If a target population dataset is available, an alternative is to weight the trial sample to mimic
the target population distribution of X, Z, before implementing the same steps as in method 1.
Simulations (see description and full results in the S1 Appendix) found that Method 2 has
an advantage over method 1 with respect to bias; it provides some protection against bias due
to misspecification of the outcome model. Specifically, if the outcome model is misspecified
with respect to Z, method 1 is biased, but method 2 is unbiased because the weighting adjusts
for the difference between the trial and target population in effect variation due to the differ-
ence in distribution of Z. Also, if the outcome model is misspecified with respect to V then
both methods are biased, but if V is positively correlated with Z in the trial and influences
treatment effect in the same direction as Z, method 2 is less biased than method 1, because the
weighting adjustment for Z helps partially adjust for V. Method 2’s disadvantage is that it has
larger variance than method 1, and suffers from some degree of variance underestimation—
the variance estimated based on the fitted outcome model is on average smaller than true vari-
ance. Bias and variance combined leads to the two methods both performing well when the
outcome model is correctly specified, with the method 1 confidence interval (CI) having nomi-
nal coverage (about 95%) and the method 2 CI’s coverage being only slightly smaller (around
93-94%). When the outcome model is misspecified, due to bias reduction, method 2’s CI gen-
erally has better variance than method 1’s.
Given these findings, we generally recommend method 2 (with the weighting), unless the
two methods agree on TATE point estimates, in which case method 1’s unweighted results can
be used.
Weighting procedures. Method 2 involves weighting the trial sample to mimic the target
population distribution of X, Z. In most situations where a population dataset (either P = 1
or S = 2—see Fig 1) is available, we use weighting by the odds [3, 18]. The exception is when
trial participants are part of AND can be identified within the population dataset, then inverse
probability weighting is used. If only population summary statistics are available, weighting is
generally not used. However, if information on the joint distribution of X, Z in the target pop-
ulation is available, and X, Z are discrete with few combined categories, weighting may be
implemented. See Table 3 for details on weights computation in these cases. For why they
apply, see the S2 Appendix.
Table 2. Implementation instructions.
Method 1: Outcome-model-based sensitivity analysis
Step 1 Obtain an estimate for E[Z|P = 1] (mean of Z in the target population), with confidence limits to reflect
uncertainty (unless it is known with certainty, e.g., from a full population dataset).
Step 2 Specify a plausible range for E[V|P = 1] (aka the sensitivity parameter).
• This range should ideally be informed by knowledge about this variable from other data or from the
literature regarding the target population or similar populations.
• When little information is available, a wide range can be used so that consumers of the research could
be selective in interpreting the results based on information they may have on this parameter.
Step 3 Fit to the trial data the regression model R1.
Step 4 For each of the lower and upper ends of the range specified for E[V|P = 1], obtain a corresponding
estimate of TATE (including point estimate and confidence limits).
Suppose that for E[Z|P = 1], we have a point estimate of 2 and 95% confidence interval of (1.5, 2.5); and
for E[V|P = 1], we specify a plausible range of 30 to 70. TATE corresponding to one end of this range,
e.g., the lower end (E[V|P = 1] = 30), is estimated as follows:
• Point estimate: Take a linear combination of the coefficients from model R1—based on the TATE
formula T1—using the point estimate 2 of E[Z|P = 1], that is, (βa + 2βza + 30βva). This can be done
using the lincom statement after fitting the model in Stata or using the estimate statement
when specifying the model in SAS. The output for this linear combination includes a point estimate,
standard error and confidence interval. Take the point estimate of this linear combination as the point
estimate for TATE.
• Confidence limits: Use the confidence limits (1.5 and 2.5) of E[Z|P = 1] to take two additional linear
combinations: (βa + 1.5βza + 30βva) and (βa + 2.5βza + 30βva). Consider the confidence limits of these
linear combinations: take the more extreme of their two upper confidence limits, and the more
extreme of their two lower confidence limits, as the confidence limits for TATE.
Step 5 Plot the range of TATE with confidence bounds (y-axis) against the range specified for the sensitivity
parameter E[V|P = 1] (x-axis). Specifically,
• Plot the TATE estimates corresponding to the two ends of the range obtained in step 4, each with three
points, one for the point estimate and two for the confidence limits; and
• Connect the two point estimates, the two lower confidence limits, and the two upper confidence limits,
using three straight lines.
Method 2: Weighted-utcome-model-based sensitivity analysis
Step 0 Weight the trial sample so that it resembles the target population with respect to X, Z.
Steps 1-
2
Same as in method 1
Step 3 Fit model R1 to the weighted trial sample.
Step 4-5 Same as in method 1
https://doi.org/10.1371/journal.pone.0208795.t002
An additional note: The desired result of weighting is that the arms of the trial (i) each mim-
ics the target population in the distribution of X, Z, and (ii) remain similar to each other in the
distribution of X, Z, V. We recommend a two step procedure: first checking balance between
the trial arms and adjusting via within-trial reweighting if needed; and then weighting the
(adjusted) trial sample to the target population. We do not recommend weighting each trial
arm to the target population separately, because it may distort between-arms balance on vari-
ables not observed in the target population.
What if an effect modifier is not even observed in the trial?
There are times when instead of an effect modifier observed in the trial but not in the target
population, researchers are concerned about effect modifiers that were not measured in the
trial. This may be a specific variable, e.g., addiction severity was not measured in a substance
abuse treatment trial, but it is suspected to modify treatment effect and it may very well be dis-
tributed differently between the trial and the target population. Or it may be generic, when
researchers are concerned that there is effect modification by unknown factors.
The question is whether the above-described sensitivity analyses can be extended to cover
an effect modifier U (be it a specific or generic variable) that is unobserved in the trial. Unfor-
tunately, the answer is no. It is clear from the causal model
E½YiðaÞ� ¼ b0 þ baaþ bxXi þ bzZi þ bzaZiaþ buUi þ buaUia
that if we use the approach without weighting, we would need an estimate of βza, which is
Table 3. Weighting procedures for different target population data scenarios.
Target population data Weighting procedures
A P = 1 dataset is available. Trial participants
cannot be identified in this P = 1 dataset.
Weighting-by-the-odds, i.e., weight the trial participants using
weights computed as follows
1. stacking the trial and target population datasets into one
dataset, and creating a new variable S0 coded S0 = 1 for
observations from the trial dataset, and S0 = 0 for observations
from the target population dataset
2. fitting a model using X and Z to predict S0; and for each trial
participant, obtaining the predicted probability of S0 = 1 from
that model (aka the trial participation score), psi = Pr(S0 = 1|
Xi, Zi)
3. for every trial participant, computing the weights as Wi = (1 −
psi)/psi, the odds of being in the target population dataset.
A S = 2 dataset is available. Trial participants are
either not part of the S = 2 sample, or if they are,
they cannot be identified in this S = 2 dataset.
A P = 1 dataset is available. Trial participants are
identified in this P = 1 dataset.
Inverse-probability-weighting, i.e., weight the trial participants
using weights computed as follows
1. using the target poplation dataset, creating a new variable S0
coded S0 = 1 for observations that belong to the trial
participants, and S0 = 0 for the remaining observations
2. fitting a model using X and Z to predict S0; and for each trial
participant, obtaining the predicted probability of S0 = 1 from
that model (aka the trial participation score), psi = Pr(S0 = 1|
Xi, Zi)
3. for every trial participant, computing the weights as Wi = 1/
psi, the inverse of the probability of participating in the trial.
A S = 2 dataset is available. Trial participants are
part of the S = 2 sample, and are identified in this
S = 2 dataset.
Information on the joint distribution of {X, Z} in
the target population is available.
X, Z are categorical with a small number of
combined categories.
Ratio-of-probability-weighting, specifically, weight the trial
participants using weights computed by the formula
Wi ¼
PrðX ¼ Xi;Z ¼ ZijP ¼ 1Þ
PrðX ¼ Xi;Z ¼ ZijS ¼ 1Þ
, where the numerator and
denominator are the prevalences of the {Xi, Zi} pattern in the
target population and in the trial sample, respectively.
https://doi.org/10.1371/journal.pone.0208795.t003
unidentified from the trial because U is not observed. If we use the weighting approach and
manage to equate the mean of Z between the trial sample and the target population, then we
could do without βza but instead would have to deal with the mean of U in the weighted trial
sample, an obscure quantity that is not suitable to serve as a sensitivity parameter. (For techni-
cal details, see the S3 Appendix).
Note that this is a correction of the U case results reported in [6]; the appendix explains the
error in those previous results.
Method extensions
Turning our attention back to effect modifiers that are observed in the trial but not in the tar-
get population (V), note that the last section (and [6]) addressed a simple setting. We now
offer two extensions of the sensitivity analyses to more complex situations.
Extension 1: When both pre- and post-treatment outcomes are available
and are modeled using random intercepts models
When both pre- and post-treatment measures of the outcome are available, there are several
options for modeling such data. One option is to treat the pre-treatment outcome measure as a
baseline covariate. Another option, which we consider here, is to model the combination of
both pre- and post-treatment outcomes using random intercepts models.
The simplest random intercepts model in this case is the model without covariates
E½YijjAi; Fij� ¼ c0i þ g0 þ gaAi þ gf Fij þ gfaFijAi;
where i indexes person, j indexes observation (each person has two observations), A indicates
treatment arm, F indicates whether the observation is pre-treatment (Fi1 = 0) or post-treat-
ment (Fi2 = 1), and the coefficient γfa of FA represents treatment effect. Given randomization
of treatment in the trial, when this model is fit to the trial data, γfa estimates SATE. Note that
the coefficient of FA in models with baseline covariates (X, Z, V) that may interact with A or F
but not with FA also estimates SATE; such models adjust for covariates when estimating the
average treatment effect.
For the sensitivity analyses, we assume a model with effect modification analogous to M1.
The full details, which are somewhat more complicated than are informative, are relegated to
the S4 Appendix. The key point is that this model includes not only the FA term (βfa Fij Ai),
but also interaction terms of effect modifiers with FA (βzfa Zi Fij Ai and βvfa Vi Fij Ai). The
TATE formula in this case is
TATE ¼ bfa þ bzfaE½ZjP ¼ 1� þ bvfaE½VjP ¼ 1�: ðT2Þ
This formula is used with both method 1 and method 2—when the effect modification
regression model is fit to the unweighted and weighted trial data, respectively.
While it is usually natural to clarify effect definitions before discussing models used to esti-
mate such effects, in this section we have done the opposite, starting with models first. This
choice is intentional because in the current case it is easier to point out the effect definition
after explaining the model. As FA is an interaction of treatment arm and time (post- vs. pre-
treatment), its coefficient represents a difference in difference, specifically a difference between
the two treatment conditions with respect to the difference between post- and pre-treatment
outcomes in each condition. This means the individual treatment effect definition here is the
effect of treatment on the ‘potential outcome change’ from before to after treatment. Since
pre-treatment outcome is not affected by treatment, this is equivalent to the effect of treatment
on the potential post-treatment outcome. That is, the TATE and SATE in this case are exactly
the same average effects defined in the previous section.
Extension 2: Multiplicative effects on potential outcome rate/probability/
odds, based on a log/logit link model
In the previous section, we commented that the linear model assumption is not always appro-
priate. We now extend the methods to cases where log/logit link outcome models are used
(e.g., log mean model for a count outcome, log probability or logit model for a binary out-
come). Here the individual treatment effect is defined on the multiplicative scale that matches
the model (e.g., rate ratio, risk ratio, or odds ratio), and an ATE is defined as the geometric
mean of the individual effects. Or equivalently, one could define the individual effect as the
corresponding log rate ratio, log risk ratio or log odds ratio, and have the usual definition of
ATE as the arithmetic mean of individual effects.
We describe the extension formally here using a binary outcome with logit model (leaving
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¼ b0 þ baAþ bxX þ bzZ þ bzaZAþ bvV þ bvaVA ðR3Þ
to the original or the weighted trial sample (corresponding to method 1 or 2). Define the indi-
vidual treatment effect as the odds ratio (OR) of the individual’s potential outcomes,
TEORi ¼
Pr½Yið1Þ ¼ 1�=Pr½Yið1Þ ¼ 0�
Pr½Yið0Þ ¼ 1�=Pr½Yið0Þ ¼ 0�
;
or the corresponding log OR




TElog ORi ¼ ba þ bzaZi þ bvaVi;
TEORi ¼ exp ðba þ bzaZi þ bvaViÞ:
On the log OR scale, we have the familiar formula
TATElog OR ¼ ba þ bzaE½ZjP ¼ 1� þ bvaE½VjP ¼ 1� ðT3aÞ
for TATE defined as the average of the individual effects in the target population. Note that
‘average’ in this definition means arithmetic mean. For effects defined on the OR scale, how-
ever, the arithmetic mean does not have a nice formula. Yet we can use another type of average
that is natural to quantities on a multiplicative scale and thus is both meaningful and mathe-
matically convenient in this case, the geometric mean. Defining TATE on the OR scale as the
geometric mean of the individual ORs in the target population, we obtain
TATEOR ¼ expfba þ bzaE½ZjP ¼ 1� þ bvaE½VjP ¼ 1�g: ðT3bÞ
These two TATE formulas serve as the basis for essentially the same sensitivity analyses, as
TATEOR = exp(TATElog_OR).
As an aside, an ATE defined as geometric mean of individual OR effects (termed average
causal OR) is closely related to the conditional OR routinely estimated by logistic regression
with main effects only. Indeed the latter is an approximate estimate of the former (see more
about this in the S5 Appendix).
Illustration
The analyses presented here are merely illustrative. Results should not be taken as clinically
informative. In addition to the concise presentation here, the detailed analyses can be found in
S6 Appendix, with most of the code (R-code) included in the same appendix, and some Stata
code in S7 Appendix. The data are provided in S8 and S9 Appendices.
The trial data include baseline and post-treatment CD4 counts and several baseline char-
acteristics—age in years, sex, race, and severe immune suppression (SIS). The target popula-
tion data include age groups, sex, and race. See Table 4 for a description of these variables.
As noted above, when data include pre- and post-treatment measures of the outcome, there
are more than one analysis options. Here we use random intercepts models on the combina-
tion of both measures. (For an application modeling post-treatment outcome only, see [6]).
The definition of TATE is the average effect of treatment on potential CD4 count gain, and
equivalently, the average effect of treatment on potential CD4 count post-treatment, in the
target population.
We start by analyzing the trial data. The first question is whether to model CD4 count (and
thereby consider its change) on the additive or multiplicative scale. CD4 count is a non-nega-
tive variable, so the additive scale may predict out of range, but it is also generally bounded
above, which is more restrictive on multiplicative than on additive effects. We follow the HIV
literature convention of using the additive scale for CD4 count, noting that our models may be
suboptimal in this respect.
The two treatment arms in the trial are similar but the new treatment arm has more female
patients and the old treatment arm has a higher SIS proportion (see Table 5). For the moment,
assume we have good enough balance; we will come back to this.
SATE (i.e., the average difference, between the two treatments in the trial, in CD4 count
change, or equivalently, in post-treatment CD4 counts) is estimated to be 36.6, 95% CI =
(28.0,45.2) cells/ml by a simple model with no covariates, and 35.8, 95% CI = (27.3,44.4) by a
model that adjusts for baseline covariates. Table 6 shows substantial differences in covariate
Table 4. Illustration. Data availability.
Variable Description Observed in
trial population
Pre-treatment CD4 count CD4 count, i.e., number of T-CD4 cells per ml blood, within 10 days of treatment initiation (average if more than one
available)
✔
Post-treatment CD4 count CD4 count within 10 days of two months on treatment (average if more than one available) ✔
Continuous age Age in years ✔
Categorical age 4 categories: up to 29, 30-39, 40-49, and 50+ ✔ ✔
Sex Binary, male or female ✔ ✔
Race Dichotomized as White or non-White ✔ ✔
Severe immune
suppression
Any CD4 count of 50 or lower within the baseline period ✔
https://doi.org/10.1371/journal.pone.0208795.t004
distribution between the trial sample and target population, suggesting these SATE estimates
should not be used as estimates of TATE.
Through a simple analysis examining interactions of FA with baseline covariates (e.g.,
FA�sex), covariate pairs (e.g., FA�sex�age), and cross-classifications of categorical covariates
(e.g., FA�‘nonwhite-female’), we identify that the cross-classification of race and SIS status is
an effect modifier (see Table 7). This variation in treatment effects is visualized in Fig 2.
As treatment effects vary across race-by-SIS-status categories, to obtain TATE estimates,
we need the proportions of the target population that are in these categories. Race is observed
in the target population, with 63.9% being nonwhite. SIS status (in the white and nonwhite
groups), however, is not observed. If this were a substantive study, we would comb the litera-
ture to seek a plausible range for the proportions with SIS among White and among nonWhite
people in the target population. As this is only illustrative, we specify a wide range (0.2, 0.6) for
this proportion (which covers the proportion 0.456 in the trial), and assume that this propor-
tion is the same between White and nonWhite people in the target population. With this
assumption, this single proportion with SIS in the target population is now our sensitivity
parameter.





Age (mean) 39.5 not available
Age (range) 16 to 75 13 to 80
Age groups (proportions)
29 and younger 0.107 0.341
30 to 39 0.421 0.309
40 to 49 0.348 0.247
50 and older 0.123 0.103
Sex (proportion female) 0.159 0.266
Race (proportion nonWhite) 0.471 0.639
SIS (proportion) 0.456 not available
https://doi.org/10.1371/journal.pone.0208795.t006





Age (mean) 39.4 39.5
Sex (proportion female) 0.174 0.143
Race (proportion nonWhite) 0.473 0.468
SIS (proportion) 0.437 0.475
https://doi.org/10.1371/journal.pone.0208795.t005
Table 7. Illustration. Excerpt from effect modification modela fit to trial data.
Estimate Std. Error df t value
FA 19.72150 7.862622 923 2.508260
FA � nonWhite-noSIS 23.44112 11.979436 923 1.956780
FA � White-SIS 24.93563 12.135934 923 2.054694
FA � nonWhite-SIS 21.43789 11.956149 923 1.793043
a The referent category is White-noSIS. The other covariates included are age and sex.
https://doi.org/10.1371/journal.pone.0208795.t007
A comment is warranted on assumption A3, that the range of the treatment effect modifiers
in the target population is covered by the trial. In the current example, it is apparent that we do
not have a problem with this assumption, because effect modification involves the four race-
by-SIS-status categories, all of which are present in the trial sample. What might go unnoticed
is that the age range in the trial sample (16 to 75) is smaller than that in the target population
(13 to 80), and while we did not detect any treatment effect modification by age in the trial
sample, we do not know if treatment effects for those younger than 16 or older than 75 (who
are not represented in the trial sample) are the same as or different from treatment effects for
those in the trial sample age range; this would be an area to consult clinical experts for their
judgment. In the absence of such expert knowledge, were actual age values (rather than just
age group) observed in the target population, one option would be to generalize treatment
effects only to those aged 16 to 75 in the target population. This target population trimming is
not an option in the current case as age values are not observed. In order to move forward, we
assume that there is no effect modification by age.
We now apply the outcome-model-based sensitivity analysis (method 1) with the specified
(0.2, 0.6) range for the sensitivity parameter (proportion with SIS in the target population).
This obtains a range of TATE estimates from 36.2, 95% CI = (25.9,46.6) (corresponding to the
lower end of the sensitivity parameter range) to 39.3, 95% CI = (30.0,48.6) (corresponding to
the upper end of the sensitivity parameter range).
To apply the weighted-outcome-model-based sensitivity analysis (method 2), we need to
weight the trial data to mimic the target population with respect to covariates observed in both
(age group, sex, race). Heeding the recommendation of the two-step procedure, we first adjust
the between-arms balance in the trial sample by inverse treatment propensity score weighting.
Note that this results in a balance-adjusted SATE estimate of 33.9, 95% CI = (25.4, 42.3), which
is very similar to (but slightly smaller than) the original SATE estimates. The effect modifica-
tion model fit to the balance-adjusted trial data is very similar to that fit to the raw trial data.
If we use that model and apply method 1, we obtain TATE estimates ranging from 34.2, 95%
CI = (23.5, 44.8) to 37.1, 95% CI = (28.5, 45.7); these are slightly lower than those based on the
model fit to the raw data. To use method 2, after adjusting within-trial balance, we weight the
adjusted trial sample to the target population, using the weighting-by-the-odds procedure
described in Table 3. This results in covariate balance shown in Table 8. The ATE in this
Fig 2. Illustration. Visualization of effect modification model.
https://doi.org/10.1371/journal.pone.0208795.g002
weighted trial sample (which we will refer to as the (X, Z)- adjusted ATE) is 37.4, 95% CI =
(27.0, 47.8), which is slightly higher than our SATE estimates. This is consistent with the fact
that the weighted trial sample has higher nonWhite and SIS proportions than the original trial
sample.
We now fit the same effect modification model to the weighted trial sample (see model fit
in Table 9). Interestingly, the coefficients have changed substantially from the model fit to raw
data (Table 7). This is not surprising as it could be a result of model misspecification (which
we suspected), and it underscores our recommendation to use the weighted method so that
the model that is the basis for estimating (sensitivity analysis of) TATE is the model fit to data
that is close to the target population with respect to observed variables.
Generally we should not read much into the (lack of) statistical significance of interaction
terms in the weighted model because weighting increases variance. However, the underwhelm-
ing coefficients in the fitted model above suggest that in the weighted dataset, there is not
much differentiation of the group specific effects, and one could argue for using the (X, Z)-
adjusted ATE as an estimate of TATE.
Or we could choose to proceed with a full implementation of method 2. Based on this effect
modification model, we obtain TATE estimates ranging from 38.4, 95% CI = (26.0,50.9) (cor-
responding to the lower end, 0.20, of the range of the sensitivity parameter) to 37.5, 95% CI =
(27.4,47.7) (corresponding to the upper end, 0.60, of the range of the sensitivity parameter).
Results from both methods are plotted in Fig 3. In this particular case, as there is not a clear
slope of TATE estimates on the sensitivity parameter, we could combine these results to con-
clude that when between 20 and 60% of the target population have SIS, we could expect the tar-
get population average effect of the new treatment (relative to the old treatment) to be a gain
in CD4 count of about 36 to 39 cells per ml (point estimate) with lower and upper confidence
bounds of 26 and 51.







Age (mean) 35.8 36.1 not available
Age (range) 16 to 75 16 to 75 13 to 80
Age groups (proportions)
29 and younger 0.349 0.333 0.341
30 to 39 0.304 0.313 0.309
40 to 49 0.247 0.246 0.247
50 and older 0.100 0.107 0.103
Sex (proportion female) 0.272 0.260 0.266
Race (proportion nonWhite) 0.642 0.636 0.639
SIS (proportion) 0.515 0.522 not available
https://doi.org/10.1371/journal.pone.0208795.t008
Table 9. Illustration. Excerpt from effect modification model fit to trial data that have been weighted to the target
population.
Estimate Std. Error z value
FA 32.903852 11.93896 2.76
FA � nonWhite-noSIS 9.335134 15.74757 0.59
FA � White-SIS 4.593148 14.53369 0.32
FA � nonWhite-SIS 3.294465 15.46597 0.21
https://doi.org/10.1371/journal.pone.0208795.t009
Discussion
Policy-makers may want to use trial results to inform decisions for specific target populations.
There are now methods to calibrate trial results to target populations, increasing potential for
evidence-based decision-making [19]. However, these methods generally rely on a strong
assumption that all effect modifiers differentially distributed between sample and population
are observed and can be adjusted for. In this paper, we describe sensitivity analyses when this
is not the case. Sensitivity analyses such as these allow researchers and decision-makers to have
more appropriate confidence about population effects.
The methods proposed in this paper address situations where the effect definition matches
the model assumed—additive effect with linear model, ratio effect with logit/log link model.
While this kind of pairing is natural and commonplace, it is somewhat restrictive; there are sit-
uations where the effect definition of policy interest may not be on the same effect scale that
best matches the model scientifically deemed appropriate. Our ongoing work aims to provide
sensitivity analyses to situations where the model assumed is nonlinear but the effect scale of
interest is additive.
That these sensitivity analyses rely on the assumption of a specific causal model deserves
discussion, as the assumed model may or may not be close to the truth. Method 2, which com-
bines this model with weighting, provides some protection against model misspecification,
and thus has a flavor of double robustness. It is not truly doubly robust, however, because the
weighting does not adjust for difference in the distribution of the partially unobserved effect
modifier V. An area for further development is the search for sensitivity analysis procedures
that are more flexible regarding model assumptions.
A challenge in generalization which we commented on is that the effect modifier range cov-
erage assumption (A3) is perhaps commonly not met, because trial samples tend to be less
diverse than target populations [20]. Strategies for this situation include combining evidence
from multiple trials, combining experimental and non-experimental evidence using cross-
Fig 3. Illustration. Results from both methods.
https://doi.org/10.1371/journal.pone.0208795.g003
design synthesis [21], or redefining the population to the area with overlap [22]. These com-
plex approaches will require adapting sensitivity analyses.
Finally, it is important to note that these sensitivity analyses are not a panacea. It is best to
limit the need for them in the first place. This can be done through careful consideration of tar-
get populations when designing trials, and efforts to enroll more representative trial samples.
If that is not possible, trialists should carefully consider potential effect modifiers and investi-
gate treatment effect heterogeneity. Also, to be able to adjust for effect modifiers when general-
izing treatment effects, effect modifiers need to be measured consistently in trials and target
population datasets [5, 23]. We encourage trialists to collect covariates in the same way as is
done in common population datasets in their fields. When design strategies fall short, the
methods discussed here provide a sense for the robustness (or lack thereof) of results when
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